1. Home
  2. XERS vs BFS Comparison

XERS vs BFS Comparison

Compare XERS & BFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • XERS
  • BFS
  • Stock Information
  • Founded
  • XERS 2005
  • BFS 1993
  • Country
  • XERS United States
  • BFS United States
  • Employees
  • XERS N/A
  • BFS N/A
  • Industry
  • XERS Biotechnology: Pharmaceutical Preparations
  • BFS Real Estate Investment Trusts
  • Sector
  • XERS Health Care
  • BFS Real Estate
  • Exchange
  • XERS Nasdaq
  • BFS Nasdaq
  • Market Cap
  • XERS 752.7M
  • BFS 830.6M
  • IPO Year
  • XERS 2018
  • BFS 1993
  • Fundamental
  • Price
  • XERS $5.49
  • BFS $32.06
  • Analyst Decision
  • XERS Strong Buy
  • BFS Strong Buy
  • Analyst Count
  • XERS 6
  • BFS 1
  • Target Price
  • XERS $6.25
  • BFS $45.50
  • AVG Volume (30 Days)
  • XERS 1.8M
  • BFS 60.6K
  • Earning Date
  • XERS 08-07-2025
  • BFS 08-12-2025
  • Dividend Yield
  • XERS N/A
  • BFS 7.38%
  • EPS Growth
  • XERS N/A
  • BFS N/A
  • EPS
  • XERS N/A
  • BFS 1.47
  • Revenue
  • XERS $222,551,000.00
  • BFS $274,011,000.00
  • Revenue This Year
  • XERS $35.31
  • BFS $10.48
  • Revenue Next Year
  • XERS $19.65
  • BFS $6.52
  • P/E Ratio
  • XERS N/A
  • BFS $21.77
  • Revenue Growth
  • XERS 29.88
  • BFS 5.04
  • 52 Week Low
  • XERS $2.10
  • BFS $31.25
  • 52 Week High
  • XERS $6.07
  • BFS $42.39
  • Technical
  • Relative Strength Index (RSI)
  • XERS 62.75
  • BFS 31.81
  • Support Level
  • XERS $4.94
  • BFS $31.57
  • Resistance Level
  • XERS $5.22
  • BFS $32.98
  • Average True Range (ATR)
  • XERS 0.22
  • BFS 0.57
  • MACD
  • XERS -0.01
  • BFS -0.17
  • Stochastic Oscillator
  • XERS 86.44
  • BFS 6.07

About XERS Xeris Biopharma Holdings Inc.

Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).

About BFS Saul Centers Inc.

Saul Centers Inc is a self-managed real estate investment trust which invests in, operates and develops retail and commercial properties. The company's portfolio includes community and neighbourhood shopping centres, office properties, and mixed-use properties. Properties are located in the Washington, D.C. and Batlimore metropolitan areas. Saul Centers operates through two business segments: shopping centers, which contribute the maximum portion of total revenue; and mixed-use properties. Maximum tenants include grocery stores, discount department stores, and drug stores.

Share on Social Networks: